Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

Investors usually focus on stocks that already have stellar dividend yields, but your portfolio could also benefit from ...